



December 6, 2017
TRANS GENIC INC.
(Code No.2342 TSE Mothers)

TRANS GENIC to Launch Anti-Indoxyl Sulfate Monoclonal Antibody

TRANS GENIC INC. (CEO: Kenji Fukunaga, Fukuoka-shi, Fukuoka, Japan) hereby announces that, it will launch a new research reagent "Anti-indoxyl sulfate monoclonal antibody".

【Overview】

TRANS GENIC adopts and distributes various kinds of antibody-related products as part of its genomics business. Anti-indoxyl sulfate monoclonal antibody is developed by KUREHA CORPORATION.

Indoxyl sulfate is formed through the following metabolic pathway:

Indole is produced from dietary amino acid (L-tryptophan) by gastrointestinal bacteria, and absorbed through the intestinal tract. Then, indoxyl is produced from indole, and converted into indoxyl sulfate through sulfate conjugation in the liver.

Indoxyl sulfate is normally excreted in urine, however accumulated within the body in association with decreased renal function. It is suggested to have a causal relationship with uremia. As a result, this antibody is expected to contribute to the research on uremic toxin.

Contact for inquiries and additional information :

TRANS GENIC INC.
Yutaka Funabashi, Director
Telephone +81-(0)3-6551-2601